Next US President: no "safe" candidate

18 February 2008

The recent developments in the US presidential primary process to find the candidates for November's election have left "no 'safe' candidate for the pharmaceutical industry," according to Lehman Brothers. Although two minor candidates remain in the race for the Republican party's nomination, it seems only a matter of time before Senator John McCain (Arizona) wins, following the resignation of former Massachusetts Governor Mitt Romney.

The latter was both the promoter of a mandatory health insurance scheme in Massachusetts, which has recently experienced financial difficulties (Marketletter February 11), as well as being the only candidate in this election to defend the drug industry in public.

On the Democratic party's side, both candidates, Senators Hillary Clinton (New York) and Barack Obama (Illinois) hold largely identical views on health care reform, legalizing the use of federal funds for human embryonic stem cell research and drug reimportation from Canada (Marketletters passim). This is also likely to be the first time two current Senators have contested a presidential election in US history.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight